CY1127230T1 - Φαρμακευτικη συνθεση για απο του στοματος χορηγηση περιλαμβανουσα κρυσταλλικα αλατα του αμιδιου (4s,4as,5ar,12as)-4-διμεθυλαμινο- 3,10,12,12α-τετραϋδροξυ-7-[(μεθοξυ(μεθυλ)αμινο)- μεθυλ]-1,11 -διοξο 1,4,4α,5,5α,6,11,12α-οκταϋδρο- ναφθακενο-2-καρβοξυλικου οξεος - Google Patents
Φαρμακευτικη συνθεση για απο του στοματος χορηγηση περιλαμβανουσα κρυσταλλικα αλατα του αμιδιου (4s,4as,5ar,12as)-4-διμεθυλαμινο- 3,10,12,12α-τετραϋδροξυ-7-[(μεθοξυ(μεθυλ)αμινο)- μεθυλ]-1,11 -διοξο 1,4,4α,5,5α,6,11,12α-οκταϋδρο- ναφθακενο-2-καρβοξυλικου οξεοςInfo
- Publication number
- CY1127230T1 CY1127230T1 CY20241100739T CY241100739T CY1127230T1 CY 1127230 T1 CY1127230 T1 CY 1127230T1 CY 20241100739 T CY20241100739 T CY 20241100739T CY 241100739 T CY241100739 T CY 241100739T CY 1127230 T1 CY1127230 T1 CY 1127230T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methyl
- naphthaken
- tetrahydroxy
- octahydro
- dioxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
- C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
- C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161485179P | 2011-05-12 | 2011-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1127230T1 true CY1127230T1 (el) | 2026-02-25 |
Family
ID=47139728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20241100739T CY1127230T1 (el) | 2011-05-12 | 2024-10-17 | Φαρμακευτικη συνθεση για απο του στοματος χορηγηση περιλαμβανουσα κρυσταλλικα αλατα του αμιδιου (4s,4as,5ar,12as)-4-διμεθυλαμινο- 3,10,12,12α-τετραϋδροξυ-7-[(μεθοξυ(μεθυλ)αμινο)- μεθυλ]-1,11 -διοξο 1,4,4α,5,5α,6,11,12α-οκταϋδρο- ναφθακενο-2-καρβοξυλικου οξεος |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9255068B2 (https=) |
| EP (2) | EP2707003B1 (https=) |
| JP (5) | JP6574572B2 (https=) |
| CA (1) | CA2835876C (https=) |
| CY (1) | CY1127230T1 (https=) |
| DK (1) | DK2707003T3 (https=) |
| ES (2) | ES2739626T3 (https=) |
| HR (1) | HRP20191295T8 (https=) |
| HU (1) | HUE044536T2 (https=) |
| LT (1) | LT2707003T (https=) |
| PL (1) | PL2707003T3 (https=) |
| PT (1) | PT2707003T (https=) |
| SI (1) | SI2707003T1 (https=) |
| TR (1) | TR201911086T4 (https=) |
| WO (1) | WO2012155146A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8856782B2 (en) | 2007-03-01 | 2014-10-07 | George Mason Research Foundation, Inc. | On-demand disposable virtual work system |
| US9098698B2 (en) | 2008-09-12 | 2015-08-04 | George Mason Research Foundation, Inc. | Methods and apparatus for application isolation |
| US9255068B2 (en) * | 2011-05-12 | 2016-02-09 | Warner Chilcott Company, Llc | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
| WO2013082437A1 (en) | 2011-12-02 | 2013-06-06 | Invincia, Inc. | Methods and apparatus for control and detection of malicious content using a sandbox environment |
| CA2873412A1 (en) * | 2012-05-14 | 2013-11-21 | Paratek Pharmaceuticals, Inc. | Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide |
| HUE066360T2 (hu) * | 2016-10-19 | 2024-07-28 | Tetraphase Pharmaceuticals Inc | Eravaciklin kristályformái |
| CN111343991A (zh) * | 2017-07-21 | 2020-06-26 | 阿尔米雷尔有限责任公司 | 非炎性病变的治疗 |
| AU2019248350B2 (en) * | 2018-04-06 | 2023-07-27 | Almirall, Llc | Process for making sarecycline hydrochloride |
| JP7840880B2 (ja) * | 2020-06-11 | 2026-04-06 | パラテック ファーマシューティカルズ，インコーポレイテッド | オマダサイクリンの結晶形態、その合成方法及びその使用方法 |
| US12487293B2 (en) | 2021-06-14 | 2025-12-02 | Hioki E.E. Corporation | Short circuit detection device and short circuit detection method |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2990331A (en) | 1956-11-23 | 1961-06-27 | Pfizer & Co C | Stable solutions of salts of tetracyclines for parenteral administration |
| US2980584A (en) | 1957-10-29 | 1961-04-18 | Pfizer & Co C | Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation |
| US3062717A (en) | 1958-12-11 | 1962-11-06 | Pfizer & Co C | Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation |
| US3165531A (en) | 1962-03-08 | 1965-01-12 | Pfizer & Co C | 13-substituted-6-deoxytetracyclines and process utilizing the same |
| US3454697A (en) | 1965-06-08 | 1969-07-08 | American Cyanamid Co | Tetracycline antibiotic compositions for oral use |
| NL6607516A (https=) | 1966-05-31 | 1967-12-01 | ||
| DE1767891C3 (de) | 1968-06-28 | 1980-10-30 | Pfizer | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat |
| US3957980A (en) | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
| DE2442829A1 (de) | 1974-09-06 | 1976-03-18 | Merck Patent Gmbh | Tetracyclische verbindungen und verfahren zu ihrer herstellung |
| US4018889A (en) | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
| US4126680A (en) | 1977-04-27 | 1978-11-21 | Pfizer Inc. | Tetracycline antibiotic compositions |
| DK0599397T3 (da) | 1992-11-17 | 1996-09-16 | Univ New York State Res Found | Tetracycliner, herunder non-mikrobielle, kemisk-modificerede tetracycliner, inhiberer overdreven collagentværbinding ved diabetes |
| WO1995022529A1 (en) | 1994-02-17 | 1995-08-24 | Pfizer Inc. | 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics |
| US5789395A (en) | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
| US6277061B1 (en) | 1998-03-31 | 2001-08-21 | The Research Foundation Of State University Of New York | Method of inhibiting membrane-type matrix metalloproteinase |
| CA2892739A1 (en) * | 2006-12-21 | 2008-07-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
| WO2008079339A2 (en) | 2006-12-21 | 2008-07-03 | Paratek Pharmaceuticals, Inc. | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
| CA2717703A1 (en) * | 2008-03-05 | 2009-09-11 | Paratek Pharmaceuticals, Inc. | Minocycline compounds and methods of use thereof |
| TWI680117B (zh) * | 2008-05-19 | 2019-12-21 | 派洛泰克藥物股份有限公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
| US9255068B2 (en) * | 2011-05-12 | 2016-02-09 | Warner Chilcott Company, Llc | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
| CA2873412A1 (en) * | 2012-05-14 | 2013-11-21 | Paratek Pharmaceuticals, Inc. | Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide |
-
2012
- 2012-05-14 US US13/471,275 patent/US9255068B2/en active Active
- 2012-05-14 HR HRP20191295TT patent/HRP20191295T8/hr unknown
- 2012-05-14 CA CA2835876A patent/CA2835876C/en active Active
- 2012-05-14 EP EP12782600.6A patent/EP2707003B1/en active Active
- 2012-05-14 SI SI201231639T patent/SI2707003T1/sl unknown
- 2012-05-14 PT PT12782600T patent/PT2707003T/pt unknown
- 2012-05-14 PL PL12782600T patent/PL2707003T3/pl unknown
- 2012-05-14 ES ES12782600T patent/ES2739626T3/es active Active
- 2012-05-14 LT LTEP12782600.6T patent/LT2707003T/lt unknown
- 2012-05-14 DK DK12782600.6T patent/DK2707003T3/da active
- 2012-05-14 WO PCT/US2012/037838 patent/WO2012155146A1/en not_active Ceased
- 2012-05-14 JP JP2014510546A patent/JP6574572B2/ja active Active
- 2012-05-14 TR TR2019/11086T patent/TR201911086T4/tr unknown
- 2012-05-14 EP EP19167006.6A patent/EP3574908B8/en active Active
- 2012-05-14 ES ES19167006T patent/ES2985493T3/es active Active
- 2012-05-14 HU HUE12782600 patent/HUE044536T2/hu unknown
-
2015
- 2015-12-18 US US14/974,813 patent/US20160200671A1/en not_active Abandoned
-
2017
- 2017-02-24 JP JP2017032823A patent/JP2017132775A/ja not_active Withdrawn
-
2018
- 2018-03-06 US US15/913,504 patent/US20190040002A1/en not_active Abandoned
-
2019
- 2019-03-11 JP JP2019043868A patent/JP6876082B2/ja active Active
- 2019-05-15 US US16/412,986 patent/US20200024223A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021017922A patent/JP2021098695A/ja active Pending
-
2023
- 2023-04-04 JP JP2023060582A patent/JP2023093519A/ja active Pending
-
2024
- 2024-10-17 CY CY20241100739T patent/CY1127230T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20191295T1 (hr) | 2019-10-18 |
| HRP20191295T8 (hr) | 2020-02-07 |
| CA2835876A1 (en) | 2012-11-15 |
| CA2835876C (en) | 2020-04-14 |
| JP6574572B2 (ja) | 2019-09-11 |
| EP2707003A4 (en) | 2014-11-12 |
| US20200024223A1 (en) | 2020-01-23 |
| LT2707003T (lt) | 2019-10-10 |
| PL2707003T3 (pl) | 2019-11-29 |
| EP3574908B1 (en) | 2024-07-31 |
| JP2019142867A (ja) | 2019-08-29 |
| JP6876082B2 (ja) | 2021-05-26 |
| EP3574908B8 (en) | 2024-09-11 |
| DK2707003T3 (da) | 2019-08-05 |
| EP2707003B1 (en) | 2019-05-01 |
| JP2014520077A (ja) | 2014-08-21 |
| JP2023093519A (ja) | 2023-07-04 |
| ES2739626T3 (es) | 2020-02-03 |
| JP2021098695A (ja) | 2021-07-01 |
| JP2017132775A (ja) | 2017-08-03 |
| US20190040002A1 (en) | 2019-02-07 |
| PT2707003T (pt) | 2019-08-05 |
| WO2012155146A1 (en) | 2012-11-15 |
| HUE044536T2 (hu) | 2019-10-28 |
| EP3574908A1 (en) | 2019-12-04 |
| SI2707003T1 (sl) | 2019-10-30 |
| EP2707003A1 (en) | 2014-03-19 |
| ES2985493T3 (es) | 2024-11-06 |
| US20130012480A1 (en) | 2013-01-10 |
| US20160200671A1 (en) | 2016-07-14 |
| TR201911086T4 (tr) | 2019-08-21 |
| US9255068B2 (en) | 2016-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1127230T1 (el) | Φαρμακευτικη συνθεση για απο του στοματος χορηγηση περιλαμβανουσα κρυσταλλικα αλατα του αμιδιου (4s,4as,5ar,12as)-4-διμεθυλαμινο- 3,10,12,12α-τετραϋδροξυ-7-[(μεθοξυ(μεθυλ)αμινο)- μεθυλ]-1,11 -διοξο 1,4,4α,5,5α,6,11,12α-οκταϋδρο- ναφθακενο-2-καρβοξυλικου οξεος | |
| CY1124874T1 (el) | Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου | |
| IL254854A0 (en) | Aqueous pharmaceutical formulation of tapentadol for oral administration | |
| AR092823A1 (es) | Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimorficas y sus metodos de uso | |
| IL238477A0 (en) | Pharmaceutical dosage form for oral administration of a bcl–2 family inhibitor | |
| BR112013020002A2 (pt) | peptídeo de fórmula geral r1-wn-xm-aa1-aa2-aa3-aa4-aa5-aa6-yp-zq-r2, seus estereoisômeros, misturas dos mesmos e/ou seus sais aceitáveis de modo cosmético ou farmacêutico e composição cosmética ou farmacêutica | |
| IL211832A0 (en) | Pharmaceutical composition of a potent hcv inhibitor for oral administration | |
| EP2796461A4 (en) | PROCESS FOR THE PRODUCTION OF ICOTINIB AND ICOTINIB HYDROCHLORIDE AND INTERMEDIATES THEREOF | |
| AR085856A1 (es) | Formas cristalinas del acido (2s)-2-ter-butoxi-2-(4-(2,3-dihidropirano[4,3,2-de]quinolin-7-il)-2-metilquinolin-3-il)acetico | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| BR112013014940A2 (pt) | composições farmacêuticas de inibidores de fator xa seletivos para administração oral | |
| BR112013007904A2 (pt) | "composto, composição farmacêutica, medicamento, uso de um composto e proceso para preparar um composto" | |
| DOP2013000206A (es) | Inhibidores de la peptido desformilasa | |
| EP2849757A4 (en) | PROCESS FOR USE OF (4S, 4AS, 5AR, 12AS -) - 4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7 - [(METHOXY (METHYL) AMINO) -METHYL] -1,11-DIOXO-1 , 4.4A, 5.5A, 6,11,12a-octahydro-naphthacene-2-carboxylic acid amide | |
| PL395069A1 (pl) | Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego | |
| AR083322A1 (es) | Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo | |
| BR112013011135A2 (pt) | ''composto,método para a preparação do composto,composição farmacêutica e uso do composto'' | |
| HK1169613B (en) | Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor |